Novo Nordisk’s stock tumbles as drugmaker lays out case for declining sales in 2026
Short excerpt below. Click through to read at the original source.
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Short excerpt below. Click through to read at the original source.
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.